Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma (COACH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Asan Medical Center
Information provided by (Responsible Party):
JLee, Asan Medical Center Identifier:
First received: December 5, 2011
Last updated: September 22, 2014
Last verified: September 2014

Cisplatin-based chemotherapy is the standard regimen for advanced urothelial carcinoma.

But cisplatin-unfit patients account for up to 30-40% of patients in clinical practice.

Recently reported phase II/III trial of EORTC 30986 comparing gemcitabine/carboplatin (GCb) with MCAVI (Methotrexate, Carboplatin, Vinblastine) suggested that GCb be the preferred regimen over MCAVI based on the response rates, adverse events, and severe acute toxicities.

But the grade 3 or worse toxicities associated with GCb are not infrequent and need more effective and more tolerable regimens.

GemOx has been reported to be effective and have very favorable toxicity profiles.

Condition Intervention Phase
Advanced Urothelial Carcinoma
Drug: GCb
Drug: GemOx
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin Un-fit Advanced Urothelial Carcinoma: Randomized Phase II Study

Resource links provided by NLM:

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Response rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Response rate based on RECIST 1.1

Secondary Outcome Measures:
  • Safety [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Safety according to NCI CTCAE v.4.03

  • Progression-free survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: October 2010
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: GCb
Gemcitabine plus Carboplatin
Drug: GCb
Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
Experimental: GemOx
Gemcitabine plus Oxaliplatin
Drug: GemOx
Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cytologically of histologically confirmed urothelial carcinoma
  • Locally advanced or metastatic disease
  • Measurable disease according to RECIST v.1.1
  • ECOG PS 0-2
  • Cisplatin-unfit condition (any of the followings: NYHA functional class 3, creatinine clearance 30-60 ml/min, and ECOG PS=2)
  • Adequate organ function
  • Chemotherapy-naive

Exclusion Criteria:

  • Histology other than urothelial carcinoma, but squamous cell carcinoma or adenocarcinoma mixed with urothelial carcinoma are allowed
  • CNS metastases
  • Peripheral neuropathy grade 2 or worse
  • Serious medical or surgical conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01487915

Contact: Jae-Lyun Lee, MD, PhD 82 2 3010 5977
Contact: Jeong-Mi Ko, MSc

Korea, Republic of
Keimyeong University Dongsan Medical Center Recruiting
Daegu, Korea, Republic of, 700-712
Contact: Hong Seok Song, MD, PhD.         
Contact: Jin Young Kim, MD         
Chungnam University Hospital Recruiting
Daejeon, Korea, Republic of, 301-721
Contact: Hyo Jin Lee, MD, PhD.         
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Jeong-Mi Ko, MSc   
Principal Investigator: Jae-Lyun Lee, MD, PhD.         
Sub-Investigator: Jin-Hee Ahn, MD, PhD.         
Sub-Investigator: Hanjong Ahn, MD, PhD.         
Sub-Investigator: Jun Hyuk Hong, MD, PhD.         
Sub-Investigator: Cheryn Song, MD, PhD.         
Sub-Investigator: Cheong Soo Kim, MD, PhD.         
Korea University Anam Hospital Recruiting
Seoul, Korea, Republic of, 136-705
Contact: Kyeong Hwa Park, MD, PhD         
Chung Ang University Hospital Not yet recruiting
Seoul, Korea, Republic of, 156-755
Contact: Hee Joon Kim, MD         
Sponsors and Collaborators
Asan Medical Center
  More Information

No publications provided

Responsible Party: JLee, Associate professor, Asan Medical Center Identifier: NCT01487915     History of Changes
Other Study ID Numbers: UOSG-AMC-1001, KCSG-GU10-16
Study First Received: December 5, 2011
Last Updated: September 22, 2014
Health Authority: Korea: Food and Drug Administration

Keywords provided by Asan Medical Center:
Cisplatin-unfit condition

Additional relevant MeSH terms:
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 19, 2014